ABT-494: Eczema Study

Are you the parent of a child ages 12-17 who has been diagnosed with moderate to severe eczema? If so, your child may be eligible to participate in a study to help researchers evaluate an investigational drug called upadacitinib, which is being tested as a treatment for several inflammatory diseases, including eczema. Compensation provided.